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Increased Frequency of Ig Heavy-Chain HS1,2-A
Enhancer *2 Allele in Dermatitis Herpetiformis,
Plaque Psoriasis, and Psoriatic Arthritis
Rossella Cianci1,7, Vincenzo Giambra2,7, Claudia Mattioli2, Maria Esposito3, Giovanni Cammarota1,
Graziella Scibilia4, Giuseppe Magazzu`4, Ambrogio Orlando5, Giancarlo Sandri6, Luca Bianchi3,
Giovanni Battista Gasbarrini1, Franco Pandolfi1 and Domenico Frezza2
The enhancer DNase-hypersensitive region 1,2 (HS1,2), a member of the Ig heavy-chain 30 regulatory region
(30RR) cluster, is active in human B cells transfected with reporter genes and in mouse is activated in late
maturation. HS1,2-A contains binding sites for several transcription factors. There are four known alleles, that is,
*1, *2, *3, and *4, which differ in their lengths in transcription factor binding. We showed that in celiac disease
the frequency of the *2 allele is increased. Both dermatitis herpetiformis (DH) and psoriasis can be associated
with different frequencies with celiac disease. Thus, we further investigate the frequency of allele *2 in DH,
plaque psoriatic, and psoriatic arthritis patients. HS1,2-A allele frequencies were investigated in 37 DH, 61
plaque psoriatic, 28 psoriatic arthritis patients, and 265 healthy donors, age- and sex-matched, from the same
geographical area. The frequency of the *2 allele changes from 0.39 in controls to 0.63 in DH, 0.59 in plaque
psoriasis and 0.75 in psoriatic arthritis (P between 104–105). Our data evidence an increased frequency of the
*2 allele of HS1,2-A in these cutaneous immune-related disorders. We suggest a related genetic predisposition
in these pathogeneses.
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INTRODUCTION
Susceptibility to immune diseases is considered a multigenic
phenotype affected by a variety of genetic and environmental
or stochastic factors (Shepshelovich and Shoenfeld, 2006).
The abnormal immune response can be triggered by
interactions between susceptibility genes and environmental
factors. The most potent genetic influence on susceptibility to
immune-disorders is the major histocompatibility complex.
However, there also are non-major histocompatibility com-
plex susceptibility alleles related to immune diseases. Various
epistatic interactions are predicted to involve the multiple
genes required for disease development (Wandstrat and
Wakeland, 2001).
Accordingly, we predict that certain immunological path-
ways are common to multiple immune diseases, and other
pathophysiological mechanisms are specific to a particular
disease (Wandstrat and Wakeland, 2001). For example, the
presence of a specific antibody in an individual’s serum
combined with disease-prone major histocompatibility com-
plex haplotypes or other susceptibility loci exponentially
increases the risk for that person to develop an immune
disease in the future (Shepshelovich and Shoenfeld, 2006).
Plaque psoriasis (OMIM 177900) and psoriatic arthritis
(OMIM 607507), together with dermatitis herpetiformis (DH)
(OMIM 601230), are multi-factorial cutaneous diseases with
familial incidence and immune dependence (Karell et al.,
2002; Bowcock, 2005). Celiac disease and DH are closely
related diseases, which share a genetic background and a
common pathogenesis characterized by gluten sensitivity and
production of autoantibodies (Hervonen et al., 2000; Karell
et al., 2002). Patients with DH, which is sometime referred to
as the cutaneous phenotype of celiac disease, have asympto-
matic or frank celiac disease and a skin rash with anti-
transglutaminase (TGM) cutaneous IgA deposits. Celiac
disease and DH patients both show anti-TGM type 2
autoantibodies. Sardy et al. (2002) have shown a difference
in the pattern of anti-TGM antibodies. In fact, in addition to
anti-TGM type 2 antibodies, DH patients develop a further
ORIGINAL ARTICLE
1920 Journal of Investigative Dermatology (2008), Volume 128 & 2008 The Society for Investigative Dermatology
Received 8 March 2007; revised 6 November 2007; accepted 14 December
2007; published online 6 March 2008
The work was done in Rome and the samples were collected from different
Clinics of Roma, Messina, and Palermo, Italy
1Institute of Internal Medicine, Catholic University, Rome, Italy; 2Department
of Biology ‘‘Enrico Calef’’, Tor Vergata University, Rome, Italy; 3Department
of Dermatology, Tor Vergata University Hospital, Rome, Italy; 4Department of
Paediatrics, University Hospital, Messina, Italy; 5Department of Internal
Medicine, ‘‘V Cervello’’ Hospital, Palermo, Italy and 6Nutrition Unit, S
Eugenio Hospital, Rome, Italy
Correspondence: Professor Domenico Frezza, Department of Biology ‘‘Enrico
Calef’’, Tor Vergata University, Viale dell’Universita`, Rome 00133, Italy.
E-mail: frezza@uniroma2.it
7These authors contributed equally to this work
Abbreviations: DH, dermatitis herpetiformis; HS, DNase-hypersensitive
region; HS1,2-A, DNase-hypersensitive A region 1,2; 30RR, 30 Ig heavy-chain
regulatory region; TGM, transglutaminase
class of high-affinity antibodies against epidermal TGM or
TGM type 3. Therefore, TGM3 is the dominant autoantigen in
DH, explaining why skin symptoms rather than intestinal
symptoms appear in a proportion of patients with gluten-
sensitive disease (Sardy et al., 2002).
Plaque psoriasis, a clinically heterogeneous disease with
inherited susceptibility, is considered a T-cell-mediated
inflammatory skin disease, but humoral immune processes
have also been evaluated. Plaque psoriasis has been variously
reported to be associated with IgA-related disorders such as
celiac disease, dermatitis herpetiformis, linear IgA sub-
epidermal bullous dermatosis, IgA nephropathy, or IgA
necrotic renal glomerular vasculitis (Kallel Sellami et al.,
2006; Lapeyre et al., 2006; Zadrazil et al., 2006). Up to 16%
of psoriatic patients show the presence of IgG and IgA anti-
endomysial, anti-gliadin, and anti-TGM antibodies (Woo
et al., 2004). These celiac disease-associated antibodies in
psoriatic patients are apparently correlated with greater
disease activity. In particular, IgA anti-tissue TGM antibodies
seems to represent a lesion-associated event (Borg, 1997). A
good correlation between serum and synovial fluid anti-tissue
TGM levels was found in all inflammatory bowel patients and
in arthropathic lesions (Caspi et al., 2006). Furthermore,
psoriatic arthritis patients seem to have an increased number
of lymphocytes in the duodenal mucosa and a highly
significant increase in intraepithelial lymphocytes in compar-
ison with plaque psoriasis patients (Lindqvist et al., 2006).
Taken together, these data strongly support the idea of IgA
deregulation in these skin diseases and more generally, an
immune-alteration.
The 30 Ig heavy-chain regulatory region (30RR) enhancer
complex (Pettersson et al., 1990; Chen and Birshtein, 1997;
Mills et al., 1997) is active in murine class switch
recombination and B-cell plasma cells (Andersson et al.,
2000; Pinaud et al., 2001). The 30RR is present through many
species from mouse to apes and the orthologous enhancers
conserved (Harindranath et al., 1998; Stavnezer and Amemiya,
2004; Sepulveda et al., 2005).
In humans, the 30RR is duplicated; a copy lies downstream
of each of constant a-1 and constant a-2 genes (Chen and
Birshtein, 1997; Mills et al., 1997; Pinaud et al., 1997). The
human 30RRs contain three enhancers: DNase-hypersensitive
region 3 (HS3), HS1,2, and HS4. The central HS1,2
enhancers are polymorphic (see Figure 1; Mills et al., 1997;
Giambra et al., 2005). A significant correlation of the *2
allele of DNase-hypersensitive A region 1,2 (HS1,2-A),
downstream of a-1 gene, was shown in patients with IgA
nephropathy, and celiac disease and systemic sclerosis
(Aupetit et al., 2000; Frezza et al., 2004, 2007).
Therefore, we compared the frequencies of four alleles of
the HS1,2-A enhancer in patients with DH, plaque psoriasis,
and psoriatic arthritis with a healthy sample of the same
geographical area. A significant correlation was observed in
all three disorders, with an increase in *2 allele frequency.
RESULTS
The data reported in Table 1 show the frequencies of the four
alleles of the enhancer HS1,2-A in the group of patients with
dermatitis herpetiformis, plaque psoriasis, psoriatic arthritis,
and in a control group selected from the same geographical
area and not related at least for three generations. The
distribution of the four allele’s frequencies is similar in these
three pathological groups, but different with respect to the
control sample. In the control and pathological samples, the
observed genotypes were in agreement with Hardy–Weinberg
expected values as reported in Table 1.
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Figure 1. The human constant genes heavy-chain locus. (a) The duplication of four constant genes and relative regulatory region 30RR-1 and 30RR-2. (b)
Enlarged view of the structure of HS1,2 alleles *1 and *2 with the repeated elements of 38 bp and spacers of 17 bp; the triangle shows the position of the
consensus of NF-kB and SP1, and the parallelogram shows the consensus for OCT1. (c) Alignment of allele *1 and *2 sequences and the difference due to the
duplication of the 38-mer and internal spacer. The consensus for OCT1, NF-kB, and SP1 transcription factors are highlighted by square frames.
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The comparisons of the allelic frequencies between
pathological and healthy groups measured by a w2 signifi-
cance test showed very low P-values for DH, plaque
psoriasis, and psoriatic arthritis (Po8 104, Po2 104,
and Po105, respectively), emphasizing the strong diver-
gence from healthy group (see Table 2). In these three
diseases, the frequencies of *1, *3, and *4 alleles are
decreased compared with the control. Moreover, there is a
dramatic increase in *2 allele frequency, which is 0.63, 0.59,
0.75 in DH, plaque psoriasis, and psoriatic arthritis,
respectively, and 0.39 in the control, with an increase of
1.62, 1.50, and 1.91-fold, respectively.
These results indicate a correlation between the *2 allele’s
frequency increase and DH, plaque psoriasis, and psoriatic
arthritis. Therefore, we measured the odds ratios with the
corresponding confidence intervals, as reported in Table 3. A
similar trend characterizes the three diseases and suggests
that the presence of *2 allele associates to a clinical risk in
developing the immune-disorders (odds ratio: 2.1, 2.2, and
3.6, respectively).
DISCUSSION
In this report, we provide evidence that the HS1,2-A
enhancer *2 allele’s frequency is increased in DH, plaque
psoriasis, and arthritic psoriasis. These data suggest a possible
role for a particular allele of the enhancer HS1,2-A in these
skin disorders. However, it should be noted that the genetic
predisposition might not directly relate to cutaneous mani-
festations. The higher allele *2 frequency in psoriatic patients
with arthritis might rather suggest a role for this allele also in
the arthritic manifestations. We predict that the increased
frequency of *2 allele is not a specific marker of these three
pathological conditions, but a marker of a differential
response of Ig induction. The *2 allele could function as a
magnifier of Ig production that, in a physiological condition,
could give a favorable response. In fact in the European
population, this allele is present at such a high percent as
39%, impossible if there were not advantages to its presence
at least in heterozygotes (Giambra et al., 2006). The
frequencies of *2 allele in the three pathologies compared
with the control are different, with a highly significant w2-
value. The frequency is higher in DH and psoriatic arthritis
than in plaque psoriasis; DH and psoriatic arthritis are in fact
more rarely observed than plaque psoriasis. This difference
could be attributed to the fact that a restricted number of
factors are necessary and sufficient to trigger the onset of DH
and psoriatic arthritis compared with those of plaque
psoriasis, where many independent factors can be sufficient,
and not all are necessary, to turn on the disease.
Table 1. Frequency±SE of HS1,2-A alleles in patients with DH, plaque psoriasis, psoriatic arthritis, and healthy
control, and Hardy–Weinberg evaluation
Alleles Dermatitis herpetiformis Plaque psoriasis Psoriatic arthritis Control
*1A 0.297±0.053 (22) 0.344±0.043 (42) 0.214±0.054 (12) 0.449±0.022 (238)
*2A 0.635±0.070 (47) 0.590±0.044 (72) 0.750±0.057 (42) 0.392±0.021 (208)
*3A 0.014±0.014 (1) 0.008±0.008 (1) 0.018±0.017 (1) 0.059±0.010 (31)
*4A 0.054±0.026 (4) 0.058±0.021 (7) 0.018±0.017 (1) 0.100±0.013 (53)
Genomes 74 122 56 530
Degree of freedom 1 1 1 1
w2 4.999 2.088 0.326 1.685
P 0.05oPo0.025 0.50oPo0.25 0.75oPo0.50 0.25oPo0.10
DH, dermatitis herpetiformis; HS1,2-A, DNase-hypersensitive A region 1,2.
The number of observed genomes is indicated in parentheses.
Table 2. Test of significance of HS1,2-A allelic
frequency differences among DH, plaque psoriasis, or
psoriatic arthritis patients compared with the control
Dermatitis
herpetiformis
Plaque
psoriasis
Psoriatic
arthritis
Degree of
freedom
3 3 3
w2 16.46 18.63 22.56
P 0.0008 0.0002 o 105
DH, dermatitis herpetiformis; HS1,2-A, DNase-hypersensitive A region
1,2.
Table 3. Risk to develop DH, plaque psoriasis, or
psoriatic arthritis associated with the frequency of the
*2A allele
Dermatitis herpetiformis versus control
Degree of freedom=1 w2=8.2911 P=0.004 OR=2.136 CI=1.29–3.532
Plaque psoriasis versus control
Degree of freedom=1 w2=15.0251 P=0.0001 OR=2.229 CI=1.50–3.332
Psoriatic arthritis versus control
Degree of freedom=1 w2=17.1981 Po0.0001 OR=3.681 CI=1.96–6.902
CI, confidence interval; DH, dermatitis herpetiformis; OR, odds ratio.
w2-Test and OR with CI of the different groups of patients versus control
subjects for the *2A allele.
1With Yates correction.
2Using the approximation of Woolf.
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As far as the role of HS1,2-A is concerned, in vitro studies
demonstrated an increased enhancer activity on the lucifer-
ase gene by the HS1,2-A allele *2 compared with *1 as well
as for all the alleles harboring a higher number of repeats in
respect to the shorter ones (Denizot et al., 2001). The role of
Hs1,2-A allele *2 may be then important in modifying
immune or inflammatory responses in our patients. The most
evident difference of allele *2 in regards to allele *1 is the
presence of an extra consensus site for NF-kB and SP1 (see
Figure 1). On the basis of the immunological alterations
present in the disorders, the *2 allele prompts Ig production
to a stronger response either in terms of activation of
class switch or germinal transcription. These results may
identify a role for genetic polymorphism in the immune
regulation and its influence in B-cell activity. The analysis of
the haplotypes of the entire 30-regulatory region will provide
more information on the role of this cis-acting region in
immune-diseases.
In conclusion, our data add DH, plaque psoriasis, and
psoriatic arthritis to the growing list of disorders associated
with Ig deregulation, where the enhancer HS1,2-A may be
involved. Further studies are needed to understand its role in
the pathogenesis of the diseases and their progression. It is
interesting to note that as of now none of the whole-genome
studies in psoriasis have picked up this association. A
replication of the findings by independent research groups
with larger sample sizes will be necessary to confirm these
data.
MATERIALS AND METHODS
Patients
Thirty-seven DH patients were studied (13 males, 24 females, mean
age 36. 87±17.68 years). Diagnosis was based on standard clinical
and laboratory criteria. Granular IgA deposits in the dermal papillae
of perilesional skin were evaluated. Celiac disease was associated in
28/37 (8 males, 20 females, mean age 35.50±12.65 years). We
have also enrolled 61 patients with plaque psoriasis (39 males, 22
females, mean age 43.91±16.71 years) and 28 with psoriatic
arthritis (16 females, 12 males, mean age 47.06±13.70 years).
Diagnosis was based on clinical criteria. To exclude association with
celiac disease, all psoriatic patients were put on blood tests to assess
the presence of anti-endomysial antibody (anti-EMA) antibodies.
Two patients with anti-EMA antibodies were excluded.
The control group consists of 265 healthy Italian blood donors,
age- and sex-matched, from the same geographical areas. Genomic
DNA was extracted from total blood according to standard
procedures. All participants gave written informed consent. The
study was conducted according to the Declaration of Helsinki
Principles and the medical ethical committees of Clinics of Roma,
Messina, and Palermo approved the study.
PCR assay
To estimate the frequencies of the four alleles of HS1,2-A (GenBank
accession no.: AJ544218, AJ544219, AJ544220, AJ544221), we
carried out a selective PCR, which amplified the HS1,2-A region, but
not the identical inverted HS1,2-B region (Giambra et al., 2005).
Genomic DNA was extracted from peripheral blood nucleated cells
and amplified with the primers described previously (Giambra et al.,
2005). The cycle conditions were changed to 94 1C at 2minutes for
the first step, followed by 94 1C at 30 seconds, 61 1C at 30 seconds,
68 1C for 5minutes for 10 cycles, and 94 1C for 30 seconds, 59 1C for
30 seconds, 68 1C for 5minutes for 20 cycles, and ending with 72 1C
for 10minutes. PCRs were carried out in 50 ml of reaction volume
containing 2ml of extracted DNA (50 ng), 1.5U Platinum Taq DNA
polymerase High Fidelity (Invitrogen, Carlsbad, CA), 15 pmoles of
each primer, 1.5mM MgSO4, 50 mM each dNTP, and 1 buffer High
Fidelity (600mM Tris-SO4, pH 8.9, 180mM [(NH4)2SO4]; Invitrogen)
by using the GeneAmp PCR System 9700 (Applied Biosystems,
Foster City, CA).
To prevent carryover contamination, pre-PCR procedures were
performed with dedicated equipment in a laminar flow hood, using
aerosol-resistant plugged pipette tips (ART; Molecular Bio-Product,
San Diego, CA). Permanent devices were sterilized by ultraviolet
irradiation between usages. Negative and positive controls, without
DNA template or with a control DNA of a heterozygote, were
always included.
A nested second PCR to amplify the polymorphic core of the
enhancer HS1,2-A was performed with 1/25 of the volume of the first
PCR, avoiding carryover of the genomic DNA of the first reaction.
Control reactions were performed with 4 and 10 ng of total genomic
DNA and resulted in no visible amplification in those conditions on
agarose gel electrophoresis. The primers for the PCRs are reported by
Giambra et al. (2005). Cycle conditions were as follows: denatura-
tion step, 94 1C for 5minutes; then 94 1C for 30 seconds, 56 1C for
30 seconds, 68 1C for 60 seconds, for 30 cycles; then the last cycle at
72 1C for 2minutes (final extension step). This second PCR was
carried out with the same volumes and concentrations as in the first
PCR, except for the use of 1U of Platinum Taq DNA polymerase
(Invitrogen). PCR products were analyzed on 2.5 % agarose gel
stained with ethidium bromide.
Statistical analysis
The frequencies of the variables considered are described in
percentages. Comparisons between the frequencies of categorical
variables in different groups were performed by w2-test. P-value was
set at 0.05. Smith’s Statistical Package, version 2.80 (Pomona
College, Claremont, CA), Graphpad Instat (San Diego, CA), and Stata
6.0 TM software (College Station, TX) were used for statistical
analysis.
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